Video

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Benjamin Levy, MD, thoracic medical oncologist, clinical director, Medical Oncology, the Johns Hopkins Sidney Kimmel Cancer Center, discusses the efficacy findings of the combination of datopotamab deruxtecan (DS-1062a) and pembrolizumab (Keytruda), with or without chemotherapy, in non–small cell lung cancer (NSCLC).

The dose escalation, open label, phase 1b TROPION-Lung02 trial (NCT04526691) is examining the antibody-drug conjugate (ADC) datopotamab deruxtecan in combination with pembrolizumab, with or without chemotherapy, in patients with untreated or previously treated metastatic NSCLC.

Within TROPION-Lung02 trial, 2 cohorts of patients received the doublet of datopotamab deruxtecan and pembrolizumab, and 4 cohorts of patients were administered the ADC with pembrolizumab and carboplatin or cisplatin, Levy says. In the cohorts of treatment-naïve patients, the doublet and the triplet elicited overall response rates (ORRs) of 62% and 50%, respectively, Levy adds. The disease-control rate was 100% for the doublet and 90% for the triplet in the first-line setting, Levy continues.

In the overall population, irrespective of treatment setting, the ORRs for the doublet and triplet were 37% and 41%, respectively.

Given the durability of the responses in the first-line setting, further exploration of the datopotamab deruxtecan combinations in that setting will be vital, Levy adds. Additional studies could lead to more promising data in the future, Levy concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center